Updates are available Correction dated 2025-04-28

Article History

Received: 6 September 2024

Accepted: 17 December 2024

First Online: 5 February 2025

Change Date: 20 March 2025

Change Type: Update

Change Details: The original online version of this article was revised due to retrospective open access.

Change Date: 28 April 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12325-025-03181-z

Declarations

:

: Piotr Wiland has served as a speaker and/or advisory board member for AbbVie, AstraZeneca, Bristol Myers Squibb (BMS), Novartis, Pierre Fabre, Pfizer, Sandoz, Sobi, and UCB. Norman B. Gaylis has no conflicts of interest to declare. Charlotte Both was an employee of Hexal AG at the time of manuscript development and is a current employee of Grünenthal. Russell D. Cohen has served on the speakers’ bureau for AbbVie, BMS/Celgene, and Takeda; is a consultant for AbbVie, BMS/Celgene, Eli Lilly and Company, Genentech, Gilead Sciences, Hoffmann La-Roche, Janssen, Pfizer, Takeda, and UCB Pharma; and is a clinical trials investigator for AbbVie, BMS/Celgene, Boehringer Ingelheim, Crohn’s & Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, MedImmune, Mesoblast Ltd., Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma. Jonas Halfvarson has served as a speaker and/or advisory board member for AbbVie, Aqilion, BMS, Celgene, Celltrion, Dr Falk Pharma and the Falk Foundation, Ferring, Galapagos, Gilead, Hospira, Index Pharma, Janssen, MEDA, Medivir, Medtronic, MSD, Novartis, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, and UCB; and has received grant support from Janssen, MSD, and Takeda. Lena Lemke was an employee of Hexal AG at the time of manuscript development. Oliver von Richter is an employee of Hexal AG. Andrew Blauvelt has served as a speaker (received honoraria) for AbbVie, Eli Lilly and Company, Pfizer, and UCB; has served as a scientific advisor (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor; and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, and Ventyx.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.